May 23, 2011
After an accelerated review, the European Medicines Agency's Committee for Medicinal Products for Human Use has endorsed Victrelis (boceprevir), Merck's new hepatitis C treatment, and recommended that the European Commission grant marketing approval. The committee said Victrelis should be used in combination with interferon-based treatment in untreated patients with chronic hepatitis C, as well as in patients who had failed on treatment. The action came just a week after the drug was approved by the US Food and Drug Administration.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|No Increased Risk of Liver Cancer After Hepatitis C Treatment With Direct-Acting Antivirals|
|This Week in HIV Research: Another Person Possibly Cured of HIV; and Long-Acting Rilpivirine Suppresses HIV in Rectal Tissue|
|This Week in HIV Research: HIV-Related Inflammation May Be Irreversible; and Genetically Engineered T-Cells Resist HIV|
|How Close Are We to a Cure for HIV? A Q&A With HIV Cure Scientific Superstars|
|Dolutegravir and the Central Nervous System: A Top HIV Clinical Development of 2016|